142 related articles for article (PubMed ID: 32436296)
1. Economic benefit of prescribing an adjusted renal dose of dipeptidyl peptidase IV inhibitors in type 2 diabetes patients with chronic kidney disease.
Moon SJ; Cho YM
J Diabetes; 2020 Sep; 12(9):645-648. PubMed ID: 32436296
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
3. Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease.
Mikhail N
Postgrad Med; 2012 Jul; 124(4):138-44. PubMed ID: 22913902
[TBL] [Abstract][Full Text] [Related]
4. Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.
Kitada M; Ogura Y; Nitta K; Fujii M; Kanasaki K; Konishi K; Iida Y; Nakagawa A; Koya D
J Diabetes Investig; 2019 May; 10(3):706-713. PubMed ID: 30136384
[TBL] [Abstract][Full Text] [Related]
5. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
[TBL] [Abstract][Full Text] [Related]
6. Outcomes for Inappropriate Renal Dose Adjustment of Dipeptidyl Peptidase-4 Inhibitors in Patients With Type 2 Diabetes Mellitus: Population-Based Study.
Hong S; Han K; Park CY
Mayo Clin Proc; 2020 Jan; 95(1):101-112. PubMed ID: 31812252
[TBL] [Abstract][Full Text] [Related]
7. The MARLINA-T2D trial: putting the results into clinical perspective.
Lajara R
Expert Rev Endocrinol Metab; 2018 May; 13(3):173-176. PubMed ID: 30058901
[TBL] [Abstract][Full Text] [Related]
8. DPP-4 Inhibitors in Diabetic Patients with Chronic Kidney Disease and End-Stage Kidney Disease on Dialysis in Clinical Practice.
Abe M; Okada K
Contrib Nephrol; 2015; 185():98-115. PubMed ID: 26023019
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.
Permsuwan U; Dilokthornsakul P; Thavorn K; Saokaew S; Chaiyakunapruk N
J Med Econ; 2017 Feb; 20(2):171-181. PubMed ID: 27645706
[TBL] [Abstract][Full Text] [Related]
10. Comparison of efficacy and safety of three novel hypoglycemic agents in patients with severe diabetic kidney disease: A systematic review and network meta-analysis of randomized controlled trials.
Li Y; Hu Y; Huyan X; Chen K; Li B; Gu W; Mu Y
Front Endocrinol (Lausanne); 2022; 13():1003263. PubMed ID: 36353233
[TBL] [Abstract][Full Text] [Related]
11. Effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients with moderate to severe chronic kidney disease: Meta-analysis of randomized controlled trials using unadjusted data.
Yang M; Wang L; Gu L; Yuan W
J Diabetes; 2017 Dec; 9(12):1107-1117. PubMed ID: 28266136
[TBL] [Abstract][Full Text] [Related]
12. Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction.
Melzer-Cohen C; Karasik A; Leuschner PJ; Azuri J; Shalev V; Chodick G
Curr Med Res Opin; 2018 Oct; 34(10):1849-1854. PubMed ID: 29611727
[TBL] [Abstract][Full Text] [Related]
13. Antiproteinuric effect of DPP-IV inhibitors in diabetic and non-diabetic kidney diseases.
Nicotera R; Casarella A; Longhitano E; Bolignano D; Andreucci M; De Sarro G; Cernaro V; Russo E; Coppolino G
Pharmacol Res; 2020 Sep; 159():105019. PubMed ID: 32553713
[TBL] [Abstract][Full Text] [Related]
14. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
McGill JB; Yki-Järvinen H; Crowe S; Woerle HJ; von Eynatten M
Diab Vasc Dis Res; 2015 Jul; 12(4):249-57. PubMed ID: 25941160
[TBL] [Abstract][Full Text] [Related]
15. The effects of glucose-lowering therapies on diabetic kidney disease.
Agrawal V; Giri C; Solomon RJ
Curr Diabetes Rev; 2015; 11(3):191-200. PubMed ID: 25824237
[TBL] [Abstract][Full Text] [Related]
16. Glycemic control of type 2 diabetes mellitus across stages of renal impairment: information for primary care providers.
Tong L; Adler S
Postgrad Med; 2018 May; 130(4):381-393. PubMed ID: 29667921
[TBL] [Abstract][Full Text] [Related]
17. Comparison of heart failure risk and medical costs between patients with type 2 diabetes mellitus treated with dapagliflozin and dipeptidyl peptidase-4 inhibitors: a nationwide population-based cohort study.
Seong JM; Kim JJ; Kim HJ; Sohn HS
Cardiovasc Diabetol; 2020 Jun; 19(1):95. PubMed ID: 32571319
[TBL] [Abstract][Full Text] [Related]
18. Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.
Davis TM
Diabetes Obes Metab; 2014 Oct; 16(10):891-9. PubMed ID: 24684351
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
Park SH; Nam JY; Han E; Lee YH; Lee BW; Kim BS; Cha BS; Kim CS; Kang ES
Medicine (Baltimore); 2016 Aug; 95(32):e4543. PubMed ID: 27512877
[TBL] [Abstract][Full Text] [Related]
20. Managing glycaemia in older people with type 2 diabetes: A retrospective, primary care-based cohort study, with economic assessment of patient outcomes.
Gordon J; McEwan P; Evans M; Puelles J; Sinclair A
Diabetes Obes Metab; 2017 May; 19(5):644-653. PubMed ID: 28026911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
